Tag: FDA panel rejects Pfizer’s arthritis drug as too risky

U.S. health advisers sharply criticized an experimental arthritis drug Thursday, saying that it was too risky, even with limits on its use. The expert panel for the Food and Drug Administration voted 19-1 that the drug’s modest benefits don’t outweigh its considerable risks, even with proposed measures to restrict who gets the medicine. Pfizer is seeking FDA approval of…